Promptly following the execution of this Agreement, the Company and Scopia shall announce this Agreement by means of a joint press release in the form attached hereto as Exhibit C (the “Press Release”) on February 28, 2018.

Public Announcement. Notwithstanding anything else herein to the contrary, Borrower hereby agrees that Collateral Agent and each Lender may, in consultation with Borrower, make a public announcement of the transactions contemplated by this Agreement, and may publicize the same on its company website, in marketing materials, newspapers and other publications, and otherwise, and in connection therewith may use Borrower’s name, tradenames, logos and any information related to the transactions to the extent such information is not confidential.

Public Announcement. Borrower hereby agrees that Collateral Agent and each Lender may make a public announcement of the transactions contemplated by this Agreement, and may publicize the same in marketing materials, newspapers and other publications, and otherwise, and in connection therewith may use Borrower’s name, tradenames and logos. Collateral Agent and the Lenders may also make disclosures to the Securities and Exchange Commission or other governmental agency and any other public disclosure with investors, other governmental agencies or other related persons.

Hill Path and the Company shall announce this Agreement by means of a joint press release in the form attached hereto as [Exhibit E] (the “Press Release”) no later than 9 a.m., New York City time, on May 28, 2019.

Public Announcement. No public announcement with respect to this Agreement or any activities under the Research Program shall be made, whether directly or indirectly, by either Party without prior agreement of the other Party. A Party desiring to make public announcement shall provide the other Party with the proposed text of such announcement with sufficient time prior to public release for the other Party’s review and comments, and such desiring Party shall use its reasonable efforts to incorporate the other Party’s comments. Both Parties shall discuss in good faith and agree on the timing, nature and text of such announcement. Subject to [Section 10.7] below, either Party may make public announcement repeatedly to the extent that once it has been made pursuant to this [Section 10.6], without first obtaining the written approval of the other Party. Either Party agrees that it may include the other Party’s name and short description of its business and the collaboration on a list of strategic partners in its corporate documents to be made publicly available, including the corporate website, financial reports for its shareholders or such documents submitted to Securities and Exchange Commission in the US or similar regulatory agency in any other country.

Public Announcement. Prior to any public announcement made by the Company, Executive shall not make any public release, statement or communication concerning Executive’s acceptance of employment with the Company without the prior written approval of the Company’s Board of Directors (the “Board”) or its designee.

Public Announcement. Promptly following the Effective Date, the Parties will jointly issue a mutually agreed press release regarding the signing of this Agreement in the form attached hereto as [Schedule 11.5]. Except # as set forth in the preceding sentence or [Section 11.2] (Authorized Disclosure), # as required to comply with Applicable Law (including the rules and regulations promulgated by the United States Securities and Exchange Commission or any equivalent Governmental Authority in any country in the Territory), and # as may be expressly permitted under this [Section 11.5] (Public Announcement), neither Party will make any public announcement regarding this Agreement without the prior written approval of the other Party. Notwithstanding the foregoing, # Acceleron may make scientific publications or public announcements concerning its research, development, manufacture or commercialization activities with respect to any Product under this Agreement without Fulcrum’s prior written approval but subject to Acceleron’s obligations under this [Article 11] (Confidentiality), # Fulcrum may announce the achievement of any Milestone or the payment of any Milestone Payment; provided that # Fulcrum shall not disclose details sufficient to identify the ​ Target, or any Collaboration Molecule or Product, unless required by Applicable Law, and # Fulcrum shall provide Acceleron reasonable advance notice of any such proposed announcement, and will incorporate such reasonable comments and revisions to protect the Confidential Information of Acceleron as reasonably requested by Acceleron, and # Fulcrum will not otherwise make any publications, presentations or public announcements of any kind regarding any of the activities contemplated under this Agreement or the results of such activities without Acceleron’s prior written consent in each instance. Neither Party will use the other Party’s or its Affiliates’ name or logo in any label, press release or product advertising, or for any other promotional purpose, without first obtaining the other Party’s prior written consent.

Public Announcement. Notwithstanding anything else herein to the contrary, Borrower hereby agrees that Collateral Agent and each Lender may make a public announcement of the transactions contemplated by this Agreement, and may publicize the same on its company website, in marketing materials, newspapers and other publications, and otherwise, and in connection therewith may use Borrower’s name, tradenames, logos, and any information related to the transactions to the extent such information is not confidential.

Public Announcement. Promptly following the Effective Date, the Parties will jointly issue a mutually agreed press release regarding the signing of this Agreement in the form attached hereto as [Schedule 11.5]. Except # as set forth in the preceding sentence or [Section 11.2] (Authorized Disclosure) # as may be expressly permitted under this [Section 11.5] (Public Announcement), neither Party will make any public announcement regarding this Agreement without the prior written approval of the other Party. Notwithstanding the foregoing, # [[MyoKardia:Organization]] may make scientific publications or public announcements concerning its research, development, manufacture or commercialization activities with respect to any Product under this Agreement without Fulcrum’s prior written approval but subject to [[MyoKardia:Organization]]’s obligations under this Article 11 (Confidentiality), and # Fulcrum may announce the achievement of any Milestone or the payment of any Milestone Payment without [[MyoKardia:Organization]]’s prior written approval; provided that # Fulcrum shall not disclose details sufficient to identify any Target, or any Molecule or Product without [[MyoKardia:Organization]]’s prior written consent, unless required by Applicable Law and # Fulcrum shall provide [[MyoKardia:Organization]] reasonable advance notice of any such proposed announcement, and will incorporate such reasonable comments and revisions to protect the Confidential Information of [[MyoKardia:Organization]] as reasonably requested by [[MyoKardia:Organization]], and # Fulcrum will not otherwise make any publications, presentations or public announcements of any kind regarding any of the activities contemplated under this Agreement or the results of such activities without [[MyoKardia:Organization]]’s prior written consent in each instance. Neither Party will use the other Party’s or its Affiliates’ name or logo in any label, press release or product advertising, or for any other promotional purpose, without first obtaining the other Party’s prior written consent.

The Company shall # announce this Agreement by means of a press release in the form attached to this Agreement as Exhibit A (the “Press Release”) and # file with the SEC a Current Report on Form 8-K reporting its entry into this Agreement, disclosing applicable items to conform to its obligations hereunder and appending this Agreement as an exhibit thereto, in each case no later than 8:00 a.m., New York City time, on December 10, 2020. The Form 8-K shall be consistent with the terms of this Agreement and the Press Release. The Company shall provide the Investors and their Representatives with a reasonable opportunity to review and comment on the Form 8-K prior to the filing with the SEC and consider in good faith any comments of the Investors and their Representatives.